Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > Avalyn

<< Previous

Bullboard Posts

Next >>

Comment by Ciaoon Oct 30, 2021 11:28am

90 Views

Post# 34068130

RE:RE:RE:RE:RE: Avalyn

From their Aug 2020 NR, a good summary; the purity and particle size and size distribution for PGX Y-BG is the key advantage here over othe available forms of Y-BG. Looking forward to updated results from McMaster, hopefully in November.

“We are excited that we have been able to fabricate particles that have the targeted properties for inhalation, enabling the effective delivery of the particles to patients’ lungs pending the safety and efficacy animal trials now underway. As this project continues, our confidence in the potential of Ceapro’s materials to treat late-stage COVID-19 patients and make a real-time impact on preserving lives during the pandemic continues to build,” reported Dr. Todd Hoare.

Dr. Kjetil Ask added, “If this size optimized PGX-YBG passes the tolerability, safety and therapeutic animal tests that we have already initiated, this material could quite quickly contribute as an immune modulator and anti-fibrotic treatment option for the most severe COVID-19 patients. Additionally, and equally exciting, the possibility of using PGX-YBG as an inhalable carrier of other drugs, would potentially allow the direct delivery of additional treatment options and increase their bioavailability in the lung, while reducing potential side effects.”

In parallel to the animal studies conducted at McMaster University, Ceapro also outsourced an in-vitro study to assess the immune response of the PGX-YBG on human receptors. The activity of PGX-YBG was tested on two human Dectin isotypes (Dectin-1a and Dectin-1b) involved in the modulation of the innate human immune response. The conclusion of this in-vitro study was that PGX-YBG exhibited significant stimulatory effect on human Dectin-1a and Dectin-1b receptors. Due to the results seen in the in-vitro study, the Company expects that PGX-YBG will stimulate the human immune response once inhaled into the lungs and potentially prevent reactions like the cytokine storm. The results demonstrated in the in-vitro study were also consistent with results seen in the preliminary biological study where PGX-YBG was found to modulate the immune system without causing the undesirable side-effects associated with other yeast beta-glucan.